worldwide Industry Reports
62 followers
- Report this post
Plasma Fractionation Market Latest Sales Figure Signals More Opportunities AheadThe plasma fractionation market involves the process of separating various components from #bloodplasma to produce #therapeutic products used in the treatment of a wide range of medical conditions. Plasma fractionation plays a crucial role in providing essential therapies derived from human plasma for patients with rare and chronic diseases.Process Overview: Plasma fractionation involves the separation of blood plasma into its #constituentparts, including #proteins such as #immunoglobulins, #albumin, #clottingfactors, and other plasma-derived products. The process typically includes steps such as #fractionation, #purification, and #sterilization to produce safe and effective therapeutic products.𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅:https://lnkd.in/dKhh7cFzBy Type:ImmunoglobulinsIntravenous ImmunoglobulinsSubcutaneous ImmunoglobulinsOther ImmunoglobulinsCoagulation Factor ConcentratesFactor VIIIFactor IXVon Willebrand FactorProthrombin Complex ConcentrateFibrinogen ConcentratesFactor XIIIAlbuminProtease InhibitorsOther ProductsBy ApplicationNeurologyImmunologyHematologyCritical carePulmonologyHemato-oncologyRheumatologyOther ApplicationsCompanies Profiles in the Report:CSL (Australia), Grifols (Spain), Shire (Ireland), Octapharma (Switzerland), Kedrion Biopharma (Italy), LFB (France), Biotest (Germany), Sanquin (Netherlands), China Biologic Products (UK), Bio Products Laboratory (UK), Japan Blood Products Organization (Japan), Green Cross Corporation (South Korea), Shanghai RAAS Blood Products (China), Emergent BioSolutions (US), Intas Biopharmaceuticals (India), Bharat Serums and Vaccines Limited (India), SK Plasma (Republic of Korea), Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. (China), KabaFusion (US), Centurion Pharma (Turkey).#𝒎𝒂𝒓𝒌𝒆𝒕𝒔𝒊𝒛𝒆 #𝒎𝒂𝒓𝒌𝒆𝒕𝒕𝒓𝒆𝒏𝒅𝒔 #𝒎𝒂𝒓𝒌𝒆𝒕𝒇𝒐𝒓𝒆𝒄𝒂𝒔𝒕 #𝒎𝒂𝒓𝒌𝒆𝒕𝒂𝒏𝒂𝒍𝒚𝒔𝒊𝒔 #constituentparts, #proteins #immunoglobulins, #albumin, #clottingfactors, #fractionation, #purification, #sterilization
1
To view or add a comment, sign in
More Relevant Posts
-
IMIR Market Research Pvt. Ltd.
6,834 followers
- Report this post
Plasma Fractionation Market Size, Share & Trends Analysis Report By Product (Immunoglobulins [Intravenous Immunoglobulins, Subcutaneous Immunoglobulins, Others], Coagulation Factors, Albumin, Protease Inhibitors, Others), By Application (Immunology, Hematology, Neurology, Critical Care, Hemato-Oncology, Rheumatology, Others), By End User (Hospitals& Clinics, Clinical Research, Laboratories, Academic Institutes), COVID-19 Impact Analysis, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2022 - 2028Get A Sample Copy of This Report:https://lnkd.in/dK6D8qpYTop Players/Manufacturers:3McompanyADMA Biologics, Inc.AegrosBaxter International Inc.Bio Products Laboratory LimitedBioLife Plasma ServicesBiopharma PlasmaBiotest AGBioverativ, a Sanofi companyBoccardChina Biologic Products Holdings Inc.China National Biotec Group Company LimitedCSLEmergent BioSolutionsFUSION HEALTH CARE PVT LTD GC Biopharma (GC녹십자)GCAM, Inc.Green Cross, Inc.Grifols Egypt for Plasma Derivatives (GEPD)GrifolsHEINKEL Process Technology GmbHHemarus Therapeutics Ltd.Hualan Biological Engineering Inc.Intas PharmaceuticalsJapan Blood Products OrganizationKAMADAKedrion BiopharmaLFB Biomanufacturing Merck GroupNational Bioproducts Institute NPCOctapharmaOctapharma GermanyOctapharma SwedenPersisGenPlasma Protein Therapeutics Association (PPTA)PlasmaGen BioSciences (P) Ltd
1 Comment
Like CommentTo view or add a comment, sign in
-
Eric Chan, PhD
Professor, NUS
- Report this post
Do we know that infigratinib (Truseltiq), an oral FGFR inhibitor for advanced cholangiocarcinoma (FDA, May 2021), is metabolized to two active metabolites with similar receptor affinity? 🤔 The enzymes involved in the formation of one of the active metabolites were established via reaction phenotyping in our new #Biochemical #Pharmacology paper (Elsevier). Additionally, the potential inhibtion of liver enzymes by parent infigratinib and the two active metabolites was investigated. 👇 Kudos to Shuaibing Liu for spearheading this study! 👏 Significance: This work will help inform clinicians and scientists on the safety of infigratinib when being co-administered with other drugs. Caveat: Nonetheless, the indication was recently withdrawn (May 2024) following a voluntary request from the agents’ sponsor, QED Therapeutics, citing difficulties enrolling patients to the required confirmatory study following infigratinib’s accelerated approval. 😑 Hopefully, this does not affect our interest in the metabolism of infigratinib. Anyone clicking on the below link before August 16, 2024 will be taken directly to the final version of our article on ScienceDirect, which you are welcome to read or download. No sign up, registration or fees are required. Thanks for your interest and support! 😉 https://lnkd.in/g49HNbeX
60
See AlsoSaco Cilíndrico ClássicoESB Networks on LinkedIn: ESB Networks’ Public Safety team are attending and engaging with…4 Comments
Like CommentTo view or add a comment, sign in
-
Charles Crow
manager cardiac rehab at Ascension St Vincent's
- Report this post
Antihypertensive drug valsartan as a novel BDK inhibitorYasuyuki Kitaura1,Daichi Shindo2,Tatsuya Ogawa2,Ayato Sato3,Yoshiharu Shimomura4AffiliationsexpandPMID:33636353DOI:10.1016/j.phrs.2021.105518AbstractCatabolism of branched-chain amino acids (BCAAs) is affected by various physiological conditions and its abnormality is associated with glucose metabolism, heart disease, and neurological dysfunction. The first two steps of the BCAA metabolic pathway are common to the three BCAAs (leucine, isoleucine, and valine). The second step is an irreversible rate-limited reaction catalyzed by branched-chain α-keto acid dehydrogenase (BCKDH), which is bound to a specific kinase, BCKDH kinase (BDK), and inactivated by phosphorylation. Here, we investigated potential new BDK inhibitors and discovered valsartan, an angiotensin II type 1 receptor (AT1R) blocker, as a new BDK inhibitor. BCKDH phosphorylation and the BCKDH-BDK interaction were inhibited by valsartan in vitro. Valsartan administration in rats resulted in increased BCKDH activity by decreasing the dephosphorylated level of BCKDH complex, bound forms of BDK from BCKDH complex as well as decreased plasma BCAA concentrations. Valsartan is a novel BDK inhibitor that competes with ATP, via a different mechanism from allosteric inhibitors. The BDK inhibitor has been shown to preserve cardiac function in pressure overload-induced heart failure mice and to attenuate insulin resistance in obese mice. Our findings suggest that valsartan is a potent seed compound for developing a powerful BDK inhibitor and useful medication for treating heart failure and metabolic diseases with suppressed BCAA catabolism.
Like CommentTo view or add a comment, sign in
-
Swati Tupe
Growth Partner at Maximize Market Research Pvt. Ltd
- Report this post
The U.S. Intravenous Immunoglobulin Market: Analysis, Trends, and Growth ProspectsGet To More: https://lnkd.in/gfNMjn6yMarket Overview:The U.S. intravenous #immunoglobulin (IVIG) market plays a crucial role in providing #therapies for immune #deficiencies, #autoimmune diseases, and #neurological disorders. IVIG products are derived from human plasma and are #administered intravenously to boost the #immune system or modulate immune responses. The market is driven by increasing incidences of #autoimmune diseases, advancements in #biopharmaceutical manufacturing, and #expanding clinical #indications.Current Market Trends:Recent trends in the U.S. IVIG market include the #development of novel formulations with #improved safety profiles and extended half-lives, enhancing patient #convenience and compliance. There is also a growing preference for #subcutaneous immunoglobulin (SCIG) therapy, which offers at-home #administration options. Additionally, regulatory #approvals for new #indications and #expanded use in off-label conditions are expanding the market's reach.Growth Prospects:Looking ahead, the U.S. IVIG market is expected to #experience steady growth, fueled by aging #populations, increasing awareness of immunodeficiency #disorders, and ongoing research into new therapeutic applications. The market #dynamics include competitive pricing strategies, consolidation among #manufacturers, and efforts to address supply chain challenges. Innovations in #biotechnology and #personalized medicine are likely to shape the future #landscape of #IVIG therapies in the U.S.Key players in the U.S. Intravenous Immunoglobulin Market:• Biotest AG• Octapharma AG• LFB-BIOTECHNOLOGIES S.A.S• China Mobile International Limited Biologics Products Holdings, Inc.• Grifols, S.A.#IVIG #ImmunoglobulinTherapy #AutoimmuneDiseases #NeurologicalDisorders #Biopharmaceuticals #Immunodeficiency #Biotechnology #ClinicalIndications #HealthcareMarket #PatientCare #Immunotherapy #SCIG #PersonalizedMedicine #MedicalInnovation #HealthcareTrends
1
Like CommentTo view or add a comment, sign in
-
Abhivandan Nagia
Director at ABNewswire
- Report this post
Chemiluminescence Immunoassay Market worth $19.0 billion by 2028: The global chemiluminescence immunoassay market in terms of revenue was estimated to be worth $13.2 billion in 2023 and is poised to reach $19.0 billion by 2028, growing at a CAGR of 7.5% from 2023 to 2028 Browse 181 market … Continue reading → #HealthMedicine #PharmaceuticalsBiotech #UK #US #World
Like CommentTo view or add a comment, sign in
-
Ben Cook
Building Global SaaS teams across the world! Teem - GTM SaaS Headhunters
- Report this post
🥊 Combination Therapy VS Viral Hepatitis 🥊 A recent article i read discusses the potential of combination therapy with bulevirtide and pegylated interferon alfa-2a (PegIFN) as a finite treatment option for adults with chronic hepatitis delta virus (HDV). The findings are based on the final Phase IIb data from the MYR204 study by Gilead Sciences.3 Key takeaways from this read:🚨 Efficacy of Combination Therapy: The combination of bulevirtide 10mg with PegIFN showed a 46% rate of undetectable HDV RNA at Week 48 after the end of treatment, compared to lower rates with monotherapies.🚨 Study Results: The MYR204 study demonstrated that bulevirtide 10mg in combination with PegIFN maintained a higher rate of undetectable HDV RNA compared to bulevirtide 2mg in combination with PegIFN, PegIFN monotherapy, and bulevirtide 10mg monotherapy.🚨 Potential for Finite Treatment: The data supports the potential for bulevirtide as a finite treatment option, with almost half of the patients treated with the combination therapy remaining undetectable for HDV RNA one year after treatment cessation.Are you hopeful for the future of combination therapy??Thank you Catherine Eckford (European Pharmaceutical Review) for a great read! https://lnkd.in/eEPwY-bn#CRO #cro #Gileadsciences #Gilead #ContractResearch #Hepatitis #Research #RND #Development #MYR204
14
Like CommentTo view or add a comment, sign in
-
Omar Mahmoud
MediHelp App Founder
- Report this post
Let's talk about the medication Allopurinol 💊, which has a notable 🔎 history and is primarily used in the treatment of gout. 🦶Allopurinol was first developed in the 1950s 🗓️ by biochemist Gertrude B. Elion and her colleague George H. Hitchings at the pharmaceutical company Burroughs Wellcome (now part of GlaxoSmithKline) 🏢.They were awarded the Nobel Prize in Physiology or Medicine in 1988 for their work on the drug's development, along with Sir James W. Black. 🥇Allopurinol is a xanthine oxidase inhibitor, which means it inhibits the activity of the enzyme xanthine oxidase. This enzyme is involved in the production of uric acid, a substance that can form crystals in the joints and tissues, leading to the painful symptoms of gout.⚙️By inhibiting xanthine oxidase, Allopurinol reduces the production of uric acid, thereby preventing gout attacks. ⚕️The drug was approved by the FDA in 1966 and has since become the standard of care for chronic gout management. ✅It is also used to treat hyperuricemia (high levels of uric acid in the blood) and is sometimes prescribed to prevent the recurrence of kidney stones that are related to high uric acid levels. ✅Additionally, Allopurinol is used in the treatment of certain types of cancer 🧐, such as leukemia, to prevent the buildup of uric acid that can occur when large numbers of tumor cells are destroyed rapidly (tumor lysis syndrome). 🥼Allopurinol's development and its subsequent impact on the treatment of gout and hyperuricemia demonstrate the importance of understanding biochemical pathways in the design of effective medications. 💊 🥼⚕️Sources:- Elion GB. The purine path to chemotherapy. Science. 1989 Apr 28;244(4900):41-7. doi: 10.1126/science.2649981.- Pacher P, Nivorozhkin A, Szabó C. Therapeutic effects of xanthine oxidase inhibitors: Renaissance half a century after the discovery of allopurinol. Pharmacol Rev. 2006 Mar;58(1):87-114. doi: 10.1124/pr.58.1.6.
51
2 Comments
Like CommentTo view or add a comment, sign in
-
Alison Porter
Biopharmaceutical development expert | CMC development expert | Mammalian cell culture expert (cell line development and upstream process development)
- Report this post
A report on some work looking at using ectoine as a productivity enhancer in mAb producing CHO cells. Inreases in productivity were seen with 100mM ectoine and the authors report on work investigating how this is achieved through the addition of this supplement.#cho #productivityenhancer #cellculture #cellculturemedia #mab #biopharmaceuticalshttps://lnkd.in/e2Cy6w-B
19
Like CommentTo view or add a comment, sign in
-
Bahman Onagh٫ PhD
Biotechnologist, Qualified Person in NAT laboratory
- Report this post
With contributions from an international team of eighty leading experts and pioneers in the field, Production of Plasma Proteins for Therapeutic Use presents a comprehensive overview of the current state of knowledge about the function, use, and production of blood plasma proteins. In addition to details of the operational requirements for the production of plasma derivatives, the book describes the biology, development, research, manufacture, and clinical indications of essentially all plasma proteins with established clinical use or therapeutic potential.Production of Plasma Proteins for Therapeutic Use covers the key aspects of the plasma fractionation industry in five sections:Section 1: Introduction to Plasma Fractionation initially describes the history of transfusion and then covers the emergence of plasma collection and fractionation from its earliest days to the present time, with the commercial and not-for-profit sectors developing into a multi-billion dollar industry. Section 2: Plasma Proteins for Therapeutic Use contains 24 chapters dedicated to specific plasma proteins, including coagulation factors, albumin, immunoglobulin, and a comprehensive range of other plasma-derived proteins with therapeutic indications. Each chapter discusses the physiology, biochemistry, mechanism of action, and manufacture of each plasma protein including viral safety issues and clinical uses. Section 3: Pathogen Safety of Plasma Products examines issues and procedures for enhancing viral safety and reducing the risk of transmissible spongiform encephalopathy transmission. Section 4: The Pharmaceutical Environment Applied to Plasma Fractionation details the requirements and activities associated with plasma collection, quality assurance, compliance with regulatory requirements, provision of medical affairs support, and the manufacture of plasma products. Section 5: The Market for Plasma Products and the Economics of Fractionation reviews the commercial environment and economics of the plasma fractionation industry including future trends, highlighting regions such as Asia, which have the potential to exert a major influence on the plasma fractionation industry in the twenty-first century
38
Like CommentTo view or add a comment, sign in
-
Eurofins DiscoverX
5,003 followers
- Report this post
💡Peptide therapeutics focusing on #metabolictargets such as GLP-1, GIP, & glucagon (GCG) are on the rise! Explore the existing & upcoming suite of Eurofins DiscoverX® assays for characterizing a variety of #GPCR targets, particularly for #obesity & #diabetes with MOA-reflective assays.Whether its innovator drugs, #biosimilars, or small molecules, accelerate their development with ease using functional, ready-to-use cell-based assay solutions… all the way from screening to potency testing in QC lot release. Get your obesity & diabetes #therapeutics to market faster!Discover how: https://lnkd.in/e_USWHti
69
1 Comment
Like CommentTo view or add a comment, sign in
62 followers
View Profile
FollowMore from this author
- Construction Equipment Industry Research Study worldwide Industry Reports 1mo
- Natural Sweeteners Industry Status and analysis worldwide Industry Reports 1mo
- Medical Morphine Industry Overall Study Report worldwide Industry Reports 1mo
Explore topics
- Sales
- Marketing
- IT Services
- Business Administration
- HR Management
- Engineering
- Soft Skills
- See All